Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Agnosia × Psilocybin × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Neoplasms 8 Depression 7 Anxiety Disorders 6 Neoplasm Metastasis 3 Depressive Disorder, Major 2 Pancreatic Neoplasms 1 Ovarian Neoplasms 1 Osteosarcoma 1 Opioid-Related Disorders 1 Melanoma 1 Lymphoma 1 Hospice 1 Hematopoietic and Lymphatic System Neoplasm 1 Hematologic Neoplasms 1 Gastrointestinal Neoplasms 1 Endocrine Gland Neoplasms 1 Depressive Disorder 1 Caregiver Distress 1 Carcinoma, Non-Small-Cell Lung 1 Breast Neoplasms 1 Biliary Tract Neoplasms 1 Agnosia 1

Interventions

Bupivacaine 9 Ketamine 8 Dexmedetomidine 7 Analgesics, Opioid 7 Ropivacaine 6 Anesthesia, General 6 Acetaminophen 6 Lidocaine 5 Fentanyl 5 Acupuncture Therapy 5 Tramadol 4 Surveys and Questionnaires 4 Sodium Chloride 4 Morphine 4 Ethanol 4 Anesthesia, Local 4 parecoxib 3 Saline Solution 3 Radiofrequency Ablation 3 Propofol 3 Ketorolac 3 Control Groups 3 Anesthetics, Local 3 Analgesia, Epidural 3 Transcutaneous Electric Nerve Stimulation 2 Tea 2 Pregabalin 2 Oxycodone 2 Magnesium Sulfate 2 Levobupivacaine 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06001749 2025-12-16

Psilocybin in Cancer Pain Study

Dana-Farber Cancer Institute

Phase 2 Recruiting

Agnosia, Opioid-Related Disorders

Data powered by HemOnc (CC BY 4.0) Colophon ⚡